Notice for apalutamide (Janssen-Cilag Pty Ltd)
Active ingredients
apalutamide
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Tablet
Indication
For the treatment of patients with castration-resistant prostate cancer at risk of developing metastases
Registration date